overweight or obese is associated with improved survival whereas being underweight is associated with increased mortality. Indeed, some study had demonstrated the protective effect of high BMI seems limited to high muscle mass, not high fat mass. 11 There were several methods to measure lean muscle mass and fat mass, such as dualenergy X-ray absorptiometry (DEXA) and bioimpedance analysis (BIA).
However, these methods were not available worldwide and might require repeat measurements. 12 Low serum testosterone and hypogonadism were highly prevalent in those with CKD. 13 The rate of decline in testosterone levels is higher in those with CKD, including those on dialysis. 14 It was associated with adipocyte dysfunction, insulin resistance, sarcopenia, and followed by obesity. 15 Besides, it was also linked to endothelial dysfunction, disorder of bone composition, and serum receptor activator of nuclear factor kappa-B ligand (sRANKL) levels. 16, 17 Testosterone inhibited muscle protein degradation and potentiated stem cell differentiation toward myocyte. Testosterone therapy in men with hypogonadism might produce lean muscle mass gain, increased muscle strength and size, as well as weight loss. 18, 19 Hence, testosterone levels were correlated and associated with skeletal muscle mass and low testosterone concentrations might predict long-term survival in those with CKD or dialysis. 20, 21 The aim of this study was to evaluate prognostic importance of serum testosterone in elderly men with hemodialysis and whether low testosterone levels were superior to low skeletal muscle mass in predicting mortality or not. As testosterone level predicted mortality in male HD patients was largely dependent on age, 14 we restricted our study population to elderly men to minimize the confounding effect of age and analyzed multiple risk factors and comorbid conditions at start of dialysis, including skeletal muscle mass index (SMMI), serum testosterone, BMI, and well-known risk factors for mortality after dialysis in a regional hospital. The impacts of those factors on mortality in those undergoing dialysis were followed over 5 years.
| MATERIALS AND METHODS

| Subjects
This is a retrospective observational cohort study that included 245 adult male patients receiving dialysis in Taoyuan General Hospital ). Dialysis dose (Kt/V) was estimated by urea kinetic modeling formulas. 22 Those with dialysis vintage less than 3 months (n = 6), those on peritoneal dialysis (n = 19), those with lack of demographic and biochemical data (n = 11), those undergoing dialysis with ventilator dependency (n = 2), and those younger than 65 years old were excluded (n = 70) ( Figure 1 ). Consequently, a total of 137 eligible male patients were included for analysis.
| Ethics
This study was conducted in accordance with the Declaration of Helsinki (2000) of the World Medical Association, and the protocol was approved by the institutional review board of Taoyuan General Hospital (TYGH.106011). This study was investigated in a single Non-low testosterone group N = 91 regional hospital, and all patients in the study were directly diagnosed and followed up at Taoyuan General Hospital.
| Outcome ascertainment
Demographic data, comorbidities, clinical characteristics, biochemical data, and all-cause mortality as well as the date and possible etiology of death were recorded according to electronic medical records.
Participants lost to follow-up without death confirmation were censored at the last date of follow-up. Participants who survived over the administration censor date were censored on September 30, 2017. In addition to all-cause mortality, cardiovascular death (CV death) was defined as death due to coronary heart disease, sudden cardiac death, peripheral arterial occlusive disease, and stroke. 
| Body composition measurements
Body composition parameters were measured by bioimpedance spectroscopy using physiological models and mixture equations (Cole- was in ohms, men = 1 and women = 0, and age was in years. 23 As it was reported 70% of muscle mass and 20% of fat mass were made up of water, volume of overhydration (OH) was defined by total body water minus water from muscle mass and fat mass. 24 Fluid overload, reflected by OH/ECW ≥ 15%, was estimated and adjusted in the study. 25 Sarcopenia was defined as SMMI < 8.87 in Asian men. 9 Body composition parameters measured by bioimpedance spectroscopy had been validated by gold standard methods, such as bromide dilution method for ECW, total body potassium method for ICW, DEXA for lean muscle mass and fat mass, and clinical assessment and ultrafiltration volume for fluid overload. Postdialysis BUN was obtained to calculate dialysis dose using urea kinetics modeling formula. 22 Laboratory data such as albumin, creatinine (SCr), hemoglobin (Hb), C-reactive protein (CRP), and dialysis dose (Kt/V) were measured at start of RRT. Not only body composition parameters but also total testosterone were measured concomitantly at 3-6 months after dialysis. Diagnosed comorbidities were also recorded at start of dialysis, such as diabetes (DM), hypertension (HTN), history of cancer, coronary artery disease (CAD), and congestive heart failure (CHF). CHF was defined according to the New York Heart Association (NYHA) Functional Classification, whereas CAD was defined as elevated serum troponin I and the need for revascularization.
| Statistical analysis
Continuous variables with a normal distribution were summarized as mean ± SD unless otherwise stated. Variables with a non-normal distribution are expressed as a median (interquartile range (IQR)). 
| RESULTS
| Demographic data
The cohort of the 137 elderly men were followed up for a median of sarcopenia in different tertiles was 54.3%, 4.5%, and 2.2%, respectively (P < .001). The mortality rate at the end of the 5-year study period was 44.5% (n = 61). The median time to mortality after dialysis was 24 months. The common cause of mortality during the 5-year cohort period was cardiovascular events (59.0%). Table 1 showed the comparisons between low and non-low testosterone group at start of dialysis. T A B L E 1 Baseline characteristics of study population
| Comparisons between low vs non-low testosterone groups
| The discriminative power and associations between testosterone values and death
In Table 3 ).
The association between low testosterone values and all-cause mortality was independent of general obesity, albumin, and inflammation. However, after adjusting for SMMI, the prognostic value of testosterone level was not persisted in neither all-cause nor cardiovascular death (Model 3). Figure 2 shows the survival curves for those on dialysis between low and non-low testosterone groups at baseline. The mortality was different for low vs non-low testosterone groups (82.6% vs 25.3%, log-rank χ 2 = 36.15, P < .001). As cardiovascular mortality might be confounded by competing risk of other etiologies of death, we calculated and compared cumulative incidence in competing risk data ratios. The cumulative incidence of cardiovascular and all-cause death was 33.6% and 44.5%, whereas the cumulative incidence difference of cardiovascular and all-cause death between low and non-low testosterone groups after 5 years was 29.1%(11.7%-46.4%) and 56.4%(37.7%-75.0%, Ps < .01).
Because potential mechanism of low testosterone values in predicting dialysis death was associated with low skeletal muscle mass, 
| DISCUSSION
This retrospective observational cohort study demonstrated that not only skeletal muscle mass index but also low testosterone values at baseline was associated with mortality after multivariable adjustment.
Low testosterone values were associated with low skeletal muscle mass. There was no difference between the discriminative power of SMMI and testosterone in predicting death. Baseline testosterone values were noninferior to SMMI in predicting dialysis death.
Several studies had demonstrated the association among low testosterone values, risk of cardiovascular disease, and mortality. 14, 15, 29 However, the comparisons between skeletal muscle mass and testosterone values in predicting mortality have not been well investigated.
Low testosterone values were associated with sarcopenia, low muscle strength, and physical inactivity. 15, 30 There was also dose-response relationship between testosterone therapy and gain of muscle mass as well as muscle strength. 18 Testosterone potentiated differentiation of pluripotent stem cell toward myogenic lineage and inhibited muscle protein degradation. There was also bidirectional relationship between low testosterone values and obesity as well as metabolic syndrome. 29 Hence, serum testosterone values provided survival information through associations with low skeletal muscle mass and obesity. It was also linked to endothelial dysfunction, erythropoietin-stimulating F I G U R E 2 Cumulative survival curves after commencing dialysis over 5 y for low vs non-low testosterone group Both Ps < .05 (A) all-cause death (B) cardiovascular death agents hyporesponsiveness, disorder of bone composition, inflammation, and serum receptor activator of nuclear factor kappa-B ligand levels. 16, 17, 31, 32 Testosterone might work as hemopoietic growth factor through improving iron bioavailability via the hepcidin pathway. 31 Moreover, testosterone was inversely correlated with the progress of atherosclerosis in aorta and carotid artery. 33, 34 Undoubtedly, serum testosterone levels can predict mortality. The incidence of proteinenergy wasting, which was a predictor of dialysis death, was higher in subjects with sarcopenic obesity rather than that in subjects with low muscle mass only. 1 Not surprisingly, serum testosterone, which might be an indicator of sarcopenic obesity in elderly men, was noninferior to SMMI in predicting dialysis death. In present study, we demonstrated that baseline testosterone values were noninferior to SMMI in predicting all-cause and cardiovascular death. The prognostic value of testosterone values was not persisted after adjusting for SMMI. Serum testosterone values might provide survival information for those on maintenance dialysis.
In the study, the incidence of low testosterone values was similar to previous study (50% ~ 70%). 13, 20 There were several explanations for high prevalence of low testosterone values in those with CKD.
One of them was dysfunction of hypothalamic-pituitary-gonadal axis, which resulted in decreased synthesis and secretion of serum testosterone. It was also reported low testosterone levels might predict mortality in those with advanced CKD, whereas the predictability was unclear in general population. 35 Besides, some testosterone might be removed by hemodialysis. Moreover, diurnal change and high variance of testosterone levels were also reported. 36 Low testosterone values could not be explained by increased clearance only. In the study, more than 80% of testosterone levels were measured before the noon and all blood samples were obtained before the dialysis sessions. The effect of diurnal change and in-person variance would be minimized. Although we had only single measurement of total testosterone levels, it might be reliable and representative for long-term hormone milieu in men. 37, 38 After adjusting for demographic data, body composition parameters except SMMI, and biochemical data, baseline total testosterone levels remained a significant predictor for dialysis death.
In those on dialysis, whether serum testosterone was superior to SMMI in predicting mortality was unclear. The strength of the study was to measure lean body mass precisely using body composition monitor and compare the discriminative power between serum testosterone values and SMMI in predicting dialysis death. Although the discriminative power of testosterone levels in predicting mortality was less than that of SMMI, there was no difference between the capacities of adjusted and unadjusted c-statistics (both Ps > .05).
However, there were several limitations in present study. First, it was a retrospective observational study within one medical center; therefore, the external validity was limited. Second, single measurement of total testosterone values was not representative for longitudinal and long-term testosterone levels. However, total testosterone levels declined in those on maintenance dialysis and those with normal testosterone at baseline might be reclassified nondifferentially into non-low or low testosterone groups at follow-up. The misclassification might underestimate the prevalence of androgen deficiency and biased to the null difference; thus, our finding will be more significant without misclassification. Third, SMMI measured by bioimpedance analysis was easily influenced by overhydration. We had adjusted for overhydration values to reduce the bias. Finally, estradiol levels were not measured. Estradiol level was a surrogate for visceral fat and might be associated with cardiovascular death. 18 Nonetheless, it was less strongly associated with cardiovascular death than testosterone. 39 In summary, baseline total testosterone value was a predictor for mortality after multivariate adjustment. It was noninferior to SMMI in predicting death among elderly men on dialysis. Endogenous testosterone might be a simple marker for biocomposition parameters and a cardiovascular risk factor for those on dialysis. The associations between the anabolic effect of exogenous testosterone therapy and mortality were not clear. This study was limited by the retrospective nature and sample size. A multicenter randomized control trial is warranted to confirm the association between exogenous testosterone supplement and dialysis survival.
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F I G U R E 3
The discriminative power of SMMI vs testosterone for mortality over 5 y (A) all-cause death (B) cardiovascular death
